Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. Summary
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
41.68(c) 41.81(c) 42.1(c) 43.45(c) 42.79(c) Last
21 609 212 23 720 028 32 544 072 53 822 449 28 969 377 Volume
+0.51% +0.31% +0.69% +3.21% -1.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 77 467 M - -
Net income 2021 17 986 M - -
Net Debt 2021 30 021 M - -
P/E ratio 2021 12,4x
Yield 2021 3,70%
Sales 2022 63 401 M - -
Net income 2022 15 528 M - -
Net Debt 2022 21 980 M - -
P/E ratio 2022 15,4x
Yield 2022 3,87%
Capitalization 240 B 240 B -
EV / Sales 2021 3,48x
EV / Sales 2022 4,12x
Nbr of Employees 78 500
Free-Float 59,2%
More Financials
Company
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines... 
Read more
Sector
Pharmaceuticals
Calendar
07/29Ex-dividend day for
More about the company
Ratings of Pfizer, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about PFIZER, INC.
05:32pPFIZER : Israel to give Pfizer COVID-19 booster to 60 and over as Delta spreads
AQ
04:42pPFIZER : Israel to offer 3rd COVID booster shot to older citizens
AQ
02:08pPFIZER : Israel approves Pfizer booster shot for over 60s 
AQ
01:15pExclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
RE
12:06pJOHNSON & JOHNSON : SA to Soon Administer Over 300,000 Covid-19 Vaccines a Day
AQ
12:05pAstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges
RE
11:50aPFIZER : Goldman Sachs Adjusts Pfizer's Price Target to $48 From $44, Maintains ..
MT
11:48aPFIZER : SVB Leerink Adjusts Price Target on Pfizer to $49 From $47, Maintains M..
MT
11:47aPFIZER : Morgan Stanley Adjusts Price Target on Pfizer to $45 From $42, Maintain..
MT
10:51aPFIZER INC : Goldman Sachs gives a Neutral rating
MD
09:27aASTRAZENECA : exploring options for COVID-19 vaccine business - executive
RE
07:49aPFIZER INC : RBC sticks Neutral
MD
06:15aEUROPEAN MIDDAY BRIEFING : Stocks Rise as -2-
DJ
04:24aPFIZER : Net Profit Climbs in Fiscal Q1 as Revenue Rises
MT
12:22aEMEA MORNING BRIEFING : Stocks to Open Lower After -2-
DJ
More news
News in other languages on PFIZER, INC.
03:33pIsrael will über 60-Jährigen dritte Corona-Impfung geben
07:50aBörse Stuttgart-News: Euwax Trends
04:22aISRAEL :  Grüner Pass soll steigende Corona-Zahlen bremsen
03:18aUSA : oggi atteso annuncio Biden su obbligo vaccini per federali
07/28MÄRKTE USA/Fed hält an Geldpolitik fest - Nasdaq fester
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Analysis
Moderna : Pfizer says 2021 COVID-19 vaccine sales to top $33.5 billion, sees need for boosters
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Last Close Price 42,79 $
Average target price 43,07 $
Spread / Average Target 0,65%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.16.25%243 220
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750
ABBVIE INC.10.64%209 386